Product vision |
- Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
- Potential for prophylaxis
|
MoA |
|
Key features |
Ganaplacide Novel mechanism of action – activity against parasites that are resistant to current drugs Rapid killing of parasites (parasite clearance time <48 hours) 800mg human dose stays above Minimal Parasiticidal Concentration for >8 days Transmission-blocking activity in a Standard Membrane Feeding Assay Potential for prophylaxis due to effect on parasite liver stage
Lumefantrine |
Status |
|
Next milestone |
|
Previously |
Previous names: KAF156, GNF156. Discovery partnership between MMV, Wellcome Trust, Novartis, and the Swiss Tropical and Public Health Institute
|
MMV Project Director |
|